CartiHeal
Cell-free Cartilage Regeneration
StartupCartiHeal is a Kefar Sava-based startup in the Health Tech & Life Sciences sector, established in 2009. Cell-free Cartilage Regeneration. The company has raised a total of $74M across 7 funding rounds, currently at the Acquired stage. CartiHeal was founded by Nir Altschuler. Key investors include Bioventus, Peregrine Ventures, Johnson & Johnson Innovation, among 8 total investors. The company has 11-50 employees. Core technologies: Materials & Substances, Implants.
With $74M in total funding, CartiHeal is a Acquired-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent. CartiHeal has been acquired.
- StageAcquired
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQKefar Sava
- DistrictCenter District
- StatusAcquired
- Last Round$15M
- BioventusLead
- Peregrine Ventures
- Johnson & Johnson Innovation
8 investors total
Nir AltschulerFounder & CEO
30 articles covered by sources including www.calcalistech.com,
nocamels.com,
www.prnewswire.com,
www.tech12.co.il,
en.globes.co.il.
What does CartiHeal do?
CartiHeal develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal's cell-free, off-the-shelf implant, Agili-C, is CE marked for use in cartilage and osteochondral defects. Agili-C is a rigid, biphasic, biodegradable implant. The bone phase of the implant is composed of calcium carbonate in aragonite crystalline form, a well-known biomaterial that enhances bone formation. The cartilage phase is a composite of modified aragonite and hyaluronic acid. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle, and big toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In October 2020, the the Agili-C implant was granted breakthrough device designation by the US FDA.
How much funding has CartiHeal raised?
CartiHeal has raised $74M in total funding across 7 rounds. The company is currently at the Acquired stage. Key investors include Bioventus, Peregrine Ventures, Johnson & Johnson Innovation.
Who founded CartiHeal?
CartiHeal was founded in 2009 by Nir Altschuler (Founder & CEO).
What sector is CartiHeal in?
CartiHeal operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Materials & Substances, Implants. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is CartiHeal located?
CartiHeal is based in Atir Yeda Street 17, Kefar Sava, Israel, Center District. The company also has offices abroad.